Interaction of head and neck squamous cell carcinoma cells and mesenchymal stem cells under hypoxia and normoxia.
FaDu
cell cycle
head and neck squamous cell carcinoma
hypoxia
interleukin-6
mesenchymal stem cells
normoxia
proliferation
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
01
02
2020
accepted:
23
07
2020
entrez:
24
9
2020
pubmed:
25
9
2020
medline:
25
9
2020
Statut:
ppublish
Résumé
Mesenchymal stem cells (MSCs) exhibit strong tropism towards tumor tissue. While MSCs generally surround tumors, they can also infiltrate tumors and thereby influence their proliferation. Interactions between MSCs and tumor cells are usually tested under normoxia, but the majority of solid tumors, including head and neck squamous cell carcinoma (HNSCC), are also characterized by hypoxic areas. Hence, the present study aimed to assess the interaction between MSCs and tumor cells under hypoxic conditions. MSCs were cultivated under normoxia and hypoxia, and conditioned media were used to cultivate the HNSCC cell line FaDu. The cell cycle distribution and viability of MSCs and the proliferation of FaDu cells were analyzed under normoxia and hypoxia, and changes in cytokine levels in the conditioned media were evaluated. No cell cycle changes were observed for MSCs after 24 h of cultivation under hypoxia, but the cell viability had declined. Hypoxia also led to a decrease in the proliferation of FaDu cells; however, FaDu cells proliferated faster after 48 h under hypoxia compared with normoxic conditions. This effect was reversed after incubation under normoxia for 72 h and hypoxia for 72 h. While these changes constituted a trend, these differences were not statistically significant. A cytokine assay showed an increase in interleukin (IL)-6 in the hypoxic medium. Overall, the results indicated that there was an interaction between MSCs and tumor cells. The presence or absence of oxygen seemed to influence the functionality of MSCs and their protumorigenic properties, in which IL-6 was identified as a potential mediator. Since MSCs are a component of the tumor stroma, further
Identifiants
pubmed: 32968451
doi: 10.3892/ol.2020.12092
pii: OL-0-0-12092
pmc: PMC7499978
doi:
Types de publication
Journal Article
Langues
eng
Pagination
229Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Acta Pharmacol Sin. 2013 Jun;34(6):747-54
pubmed: 23736003
Curr Med Chem. 2012;19(1):90-7
pubmed: 22300081
Int J Hematol. 2014 Apr;99(4):377-82
pubmed: 24578184
Nat Rev Cancer. 2003 Nov;3(11):807-21
pubmed: 14557817
Int J Radiat Biol Relat Stud Phys Chem Med. 1959 Jul;1:216-29
pubmed: 13820987
Int J Oncol. 2015 Jul;47(1):391-7
pubmed: 25997536
Mol Ther. 2010 Jan;18(1):223-31
pubmed: 19844197
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Eur J Cancer. 2000 Aug;36(13 Spec No):1649-60
pubmed: 10959051
Cancer Res. 2007 Jul 1;67(13):6304-13
pubmed: 17616689
Stem Cell Res Ther. 2013 Sep 17;4(5):114
pubmed: 24405819
Stem Cells. 2009 Sep;27(9):2283-92
pubmed: 19544472
J Mol Med (Berl). 2013 Mar;91(3):357-68
pubmed: 23052480
Cytotherapy. 2010 Sep;12(5):615-25
pubmed: 20230221
Viruses. 2011 Apr;3(4):398-422
pubmed: 21994739
J Exp Med. 2006 May 15;203(5):1235-47
pubmed: 16636132
Genet Vaccines Ther. 2004 Aug 13;2(1):9
pubmed: 15310406
Cancer. 1972 Jan;29(1):117-21
pubmed: 4332311
Methods Enzymol. 2004;381:335-54
pubmed: 15063685
Cell Commun Signal. 2010 Jul 16;8:18
pubmed: 20637101
Clin Sci (Lond). 2013 Feb;124(3):165-76
pubmed: 22876972
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):35-41
pubmed: 9747817
Cells Tissues Organs. 2013;198(5):327-37
pubmed: 24356396
Pathol Res Pract. 1989 Nov;185(5):551-4
pubmed: 2626364
Adv Pharm Bull. 2013;3(2):433-7
pubmed: 24312873
Mol Pharm. 2012 Sep 4;9(9):2698-709
pubmed: 22862421
Breast Cancer Res Treat. 2010 Jun;121(2):293-300
pubmed: 19597705
Cell Physiol Biochem. 2004;14(4-6):311-24
pubmed: 15319535
J Nanosci Nanotechnol. 2007 Mar;7(3):937-44
pubmed: 17450856
Stem Cells Transl Med. 2018 Sep;7(9):651-663
pubmed: 30070053
Neural Regen Res. 2013 Nov 5;8(31):2895-903
pubmed: 25206610
BMC Cell Biol. 2011 Mar 30;12:12
pubmed: 21450070
Pflugers Arch. 2006 Jun;452(3):268-75
pubmed: 16715295
Nature. 2007 Oct 4;449(7162):557-63
pubmed: 17914389
Cell Stem Cell. 2008 Sep 11;3(3):301-13
pubmed: 18786417
Circ Res. 1999 Aug 6;85(3):221-8
pubmed: 10436164
Haematologica. 2014 Jan;99(1):131-9
pubmed: 24162786
Cancer Sci. 2018 Mar;109(3):688-698
pubmed: 29284199
J Exp Clin Cancer Res. 2019 May 29;38(1):228
pubmed: 31142342
Nat Rev Clin Oncol. 2012 Dec;9(12):674-87
pubmed: 23149893
Cancer Biol Ther. 2011 Feb 1;11(3):349-57
pubmed: 21127403
Mitochondrion. 2014 Nov;19 Pt A:105-12
pubmed: 25034305
Stem Cell Res Ther. 2013 Jul 15;4(4):83
pubmed: 23856418
Cell Commun Signal. 2016 Sep 08;14(1):20
pubmed: 27608835
Clin Cancer Res. 1999 Jun;5(6):1369-79
pubmed: 10389921
Immunol Lett. 2014 May-Jun;159(1-2):55-72
pubmed: 24657523
Clin Cancer Res. 2005 Mar 1;11(5):1899-909
pubmed: 15756016
Vaccines (Basel). 2016 Nov 08;4(4):
pubmed: 27834810
J Pathol. 2003 Jul;200(4):429-47
pubmed: 12845611
Methods Mol Biol. 2012;904:173-90
pubmed: 22890932
Stem Cell Rev Rep. 2011 Sep;7(3):560-8
pubmed: 21437576
Eur Arch Otorhinolaryngol. 2007 Jul;264(7):815-21
pubmed: 17310346
Aging (Albany NY). 2019 Dec 7;11(23):11770-11792
pubmed: 31812953
Tumour Biol. 2014 Feb;35(2):1239-50
pubmed: 24136741
J Transl Med. 2014 Oct 11;12:260
pubmed: 25304688